These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10169063)

  • 1. Biotechnology: a special case for health technology assessment?
    Mason J; Drummond M
    Health Policy; 1997 Jul; 41(1):73-81. PubMed ID: 10169063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges to the economic evaluation of new biotechnological interventions in healthcare.
    Mason J
    Pharmacoeconomics; 1999 Aug; 16(2):119-25. PubMed ID: 10539393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenge of integrating monoclonal antibodies into the current healthcare system.
    Brixner DI; Bull SA
    Am J Manag Care; 1997 Jun; 3(6):903-11. PubMed ID: 10170294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of biotechnology drugs: what are the issues?
    van Rijkom J; Leufkens H; Crommelin D; Rutten F; Broekmans A
    Health Policy; 1999 Jun; 47(3):255-74. PubMed ID: 10538922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
    Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
    Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
    Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
    Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions.
    Grutters JP; Seferina SC; Tjan-Heijnen VC; van Kampen RJ; Goettsch WG; Joore MA
    Value Health; 2011; 14(5):777-84. PubMed ID: 21839418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 13. Commercial development considerations for biotechnology-derived therapeutics.
    Marafino BJ; Pugsley MK
    Cardiovasc Toxicol; 2003; 3(1):5-12. PubMed ID: 12668886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
    Bennett CL; Smith TJ; George SL; Hillner BE; Fleishman S; Niell HB
    J Clin Oncol; 1995 Sep; 13(9):2457-63. PubMed ID: 7545222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.
    Picot J; Copley V; Colquitt JL; Kalita N; Hartwell D; Bryant J
    Health Technol Assess; 2015 Aug; 19(69):1-190. PubMed ID: 26323045
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.